Regeneron Pharmaceuticals - Largest Companies by Marketcap, Revenue, Net Income and Employees
Top Corporates Hub
Regeneron Pharmaceuticals
REGN
|
NASDAQ
|
United States
235
-107
Rank
$115.11B
Market Cap
$14.20B
+$ 1.09B
+8.31%
Revenue
$4.77B
+$ 0.12B
+2.58%
Earnings
15.2K
+1.7K
+12.7%
Employees
About
Regeneron Pharmaceuticals, Inc. (REGN)
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.
- Sector: Health Technology
- Industry: Pharmaceuticals: Major
- Headquarters:
Latest News
-
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
08.06.2026 -
Regeneron: 'Buy' Revenue Growth And Two Extensive Drug Development Opportunities
08.06.2026 -
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results
05.06.2026 -
U.S. State Dept Announces Nearly $38M In Additional Funding Toward The Department's Ongoing Ebola Response Efforts
05.06.2026 -
Parabilis eyes $475m IPO to push lead asset into Phase III
05.06.2026